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The primary objective of a Phase I cancer clinical trial is to determine the maximum
tolerated dose of a drug. The “failure probability” was proposed and used as a constraint to
help identify a suitable initial dose range. The maximum tolerated dose was then deter-
mined based on a 3 þ 3 cohort-based escalation scheme. Multiple simulations were con-
ducted, and the method was evaluated according to the required sample size and accuracy
and precision of maximum tolerated dose estimate. The results indicated that the median
of the initial dose range suggested using a failure probability is a suitable initial dose
regardless of the dose escalation sequence used for a cancer Phase I study. This initial dose
required a smaller sample size and resulted in less bias of the estimated maximum
tolerated dose compared with a commonly used initial dose, that is, 10% of the lethal dose.
We tested our approach using real dose and toxicity outcome data from two published
Phase I studies. These results indicate that adding a failure probability constraint into the
calculation of the initial dose range will improve the efficiency of Phase I cancer trials.
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A Phase I cancer clinical trial is conducted to determine the
maximum tolerated dose (MTD) of a drug, which is the highest
dose at which only a predefined, acceptable proportion of
participants experience dose-limiting toxicity (DLT) [1,2].
TheMTD isdeterminedusing adose escalation scheme.Two
types of escalation schemes are commonly used: cohort-based
[3,4] and model-based [5,6] schemes. The 3 þ 3 cohort-based
scheme (3 þ 3 design) is widely used owing to its simple
method of calculating the numbers of participants who expe-
rience DLT. This design starts with a cohort of three partici-
pants. If noDLToccurs in this cohort, another threeparticipants
are recruited and given the drug at a higher dose. If one DLT
occurs, three more participants are recruited at the same dose
level. Thedose escalationproceedsuntil at least twoDLTsoccur
at a given dose. In the 3 þ 3 design, the MTD is the maximum
dose atwhich less than33%ofparticipants experienceDLT [7,8].
Common dose escalation sequences are (i) the Fibonacci
sequence (FS), in which each dose is the sum of the two pre-
vious doses [9]; (ii) the smoothedmodified Fibonacci sequence
(SMFS), which is similar to the FS but with a modification,
relative increments are 100%, 67%, 50%, 40%, and 33% there-
after, to avoid DLT with subsequent higher doses [10,11]; (iii)
the golden ratio increment sequence (GRIS), which is a 61.8%
increment in each dose, the percentage obtained from the
convergence of the FS [12]; and (iv) the multiple constant dose
increment sequence (MCDIS), in which the dose escalates by a
constant amount, usually amultiple of the initial dose [12e15].
The initial dose in a Phase I trial is usually determined from
preclinical animal studies and is calculated based on 10% of
lethal dose (LD10) in rodents, one-sixth of the highest non-
severely toxic dose in non-rodents, or no observed adverse
effect levels in tested animals and body surface area [16e18].
Too low an initial dose is unsatisfactory because it may yield a
low number of DLTs and require a large number of partici-
pants to determine the MTD. Too high an initial dose is also
unsatisfactory because it may yield too many DLTs and fail to
find the MTD. Thus, choosing the correct initial dose is of the
utmost importance in a Phase I clinical trial.
The use of probability functions to calculate the likelihood
of DLT as a function of dose has been proposed in a model-
based approach [5]. Even if the unknown toxicity function
can be arbitrarily assigned, the appropriate parameters in the
function can only be solved with additional information; once
the parameters have been estimated, however, MTD can be
estimated. Theoretically, if a 3 þ 3 design is used, the MTD is
the dose at which the probability of DLT is less than but close
to 0.33. However, a review of published Phase I trials with a





















1 TðtÞ; j ¼ 1; :::; J 1:between 0.17 and 0.26 [19]. The aim of this study was that an
initial dose should be suggested to correspond to a more ac-
curate DLT function and its dose escalation sequence.
The initial dose should be selected with caution and with
particular consideration given to obtaining the appropriate
MTD. Here we propose an approach that uses failure proba-
bility (FP) as a constraint to help choose the initial dose. We
hypothesize that use of FP to suggest initial dosewould reduce
the bias associated with the MTD and reduce the required
sample size to determine MTD.2. Methods
2.1. Dose-limiting toxicity probability function
Non-decreasing functions such as hyperbolic tangent func-
tions, probit functions, and logit functions have been used to
represent the relation between dose and toxicity [5,6,20].
Among them, the logit function is most common owing to its




 ¼ pj ¼ eaþbdj
1þ eaþbdj ;N > a > N;b > 0; (1)
where dj denotes the j
th dose corresponding to the specific
initial dose and j ¼ 1, 2, ., J, and a and b are unknowns that
can be estimated. We constrained parameter a in the logit
function to be greater than a constant in order to ensure a
positive DLT probability when the dose is zero. We then esti-
mated b with d1, where d1 is obtained based on LD10. DLT
probability at d1 is 0.01. If DLT probability is overestimated,
then the MTD estimate will be conservative. Thus, values of b
are critical to the outcome of the logit function.
2.2. Failure probability
FP can be regarded as the expected probability of a particular
dose being the MTD if the initial dose was selected appropri-
ately. It is defined as the probability that MTD fails to be
determined given J dose levels with a particular initial dose, d1,
as shown in Equation (2):





where TðjÞ is the probability of stopping the escalation at dj. Lin
and Shih [4] calculated TðjÞ from Bin(3, pj) in a 3 þ 3 design,
which is simply a cumulative probability from the binomial
distribution.
We defined P(MTD¼ dj) as the conditional probability that dj
is the MTD, as presented in Equation (3):(3)
Fig. 1 e Failure probability (FP). (A) FP versus dose for each of the four dose escalation sequences calculated using a logit DLT
functionwith a[L5.3 and b[ 0.695. The horizontal line represents 20% FP. The range indicated by the two vertical dashed
lines represents the suggested initial dose range for SMFS. (B) FP versus dose calculated using a logit DLT function with
a [ L5.3 and various values of b. Horizontal line represents 20% FP. DLT [ dose-limiting toxicity; SMFS [ smoothed
modified Fibonacci sequence.
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successfully determined before the start of the trial. A range of
suitable initial doses can be determined by solving the
inequality equation that FP is less than a certain threshold.
2.3. Sample size
The expected sample size required at each dose level was
derived by Lin and Shih [4], and we extended this calculation
to determine the expected sample size required for the whole

































MTD ¼ djÞ is the expected sample size with dj is the





p0j ð1 pjÞ3 is the probability that at
least one DLT occurred at dj (j ¼ 1, 2,., J e 1).
2.4. Simulation studies
Simulations were carried out using R version 2.15.1 (The R
Foundation for Statistical Computing, Vienna, Austria). We
used 20% as the FP constraint to determine the initial doserange and select the initial dose for use in simulations. DLT
probability for each dose escalation sequence (FS, SMFS,
GRIS, or MCDIS) was generated from the assumed true
probability using the logit function with random deviation






1þ eaþbdjþεj ; (5)
where εiidj wNð0;s2Þ and s2 represents the variability in recep-
tion to the toxic response of the drug for an individual at dj.Parameters a ¼ 5.3 and b ¼ 1.927, 1.211, 0.883, 0.816, and
0.695were used to ensure lowDLT probability at dose zero and
a smooth, increasing trend of the logit function. Simulations
were performed with s2 ranging from 0.2 to 2.0 in increments
of 0.2.
The probability of DLT occurrence was generated from
Uniform(0, 1). A DLT was regarded to have occurred if the
generated probability was smaller than the true DLT proba-
bility, whichwas generated from Equation (5). The 3þ 3 design
was followed to determine whether the dose should be raised
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been successfully estimated 1000 times for each initial dose.
Simulated expected overall sample size, average number of
DLTs, average MTD estimate, and accuracy of MTD estimate
(i.e., percentage bias) were obtained. Percentage bias is a
common metric in evaluating the simulation [21] and was
defined as ðbdMTD  dMTDÞ=dMTD  100%, where bdMTD is the esti-
mate of MTD, bdMTD ¼ 1=1000P
i¼1
1000 bdMTD;i, and dMTD is the true
MTD. Theoretically, dMTD can be solved in the DLT functions
and used as a reference value for simulation.
Data from two published studies were used to compare the
proposed method to real data.3. Results
3.1. Simulation studies
The initial dose ranges obtained for each dose escalation
sequence are displayed in Fig. 1A. The initial dose range wasFig. 2 e True percentage bias with different initial dose
ranges. The percentage bias calculated from the true DLT
function with a [ L5.3 and b [ 0.883. The x axis is the
percentile of the derived initial dose range that was used
as the initial dose. The blue bar represents the initial dose
suggested by the true DLT function. The percentage bias
was similar between the 10th and 50th percentiles of the
derived initial dose range. If the wrong DLT function (e.g.,
the same a value and b [ 0.695, 0.816, 1.211, 1.927) was
used to estimate initial dose, the suggested initial dose
range would be represented by the red bar that overlaps
the true initial dose range. The suggested initial dose was
appropriate even if the estimate of b deviated from the true
value of b because the difference in percentage bias
between the 10th and 50th percentiles of the derived initial
dose range was small and the suggested initial dose range
overlapped the initial dose range that suggested from the
true DLT function. DLT [ dose-limiting toxicity.obtained by drawing a horizontal line at 20% of FP. The FP
values calculated for the SMFS dose escalation sequence with
different initial doses using different scale parameters in the
logit DLT function are displayed in Fig. 1B. The initial dose
range became smaller as b increased for the same dose esca-
lation sequence. The initial dose range is shown in Fig. 2.
The sample size, number of DLTs, percentage bias, and
precision for each dose escalation sequence are displayed in
figures for every 10th percentile increment of the initial dose
range. Variables were calculated in this way because the ab-
solute values of the initial dose ranges were not the same
across the four dose escalation sequences and across different
b values. Only the results obtained with a ¼ 5.3, b ¼ 0.695,
and s ¼ 1.2 are presented because other results were similar.
Fig. 3A shows the total sample size and number of DLTs in
the simulated Phase I trial. These results indicated that 9.5
participants would be needed and DLT would be expected in
2.8 participants if SMFS was used and the 50th percentile
(median) of the derived initial dose range was used as the
initial dose. The required sample size decreased when the
initial dose increased within the derived initial dose range.
The results indicated that smaller sample sizes were needed
when SMFS or MCDIS was used as the dose escalation
sequence than when FS or GRIS was used as the dose esca-
lation sequence. The average number of participants with DLT
was approximately three in each simulation for all doses, as
expected for a 3 þ 3 design.
The percentage bias of MTD was always negative because
estimates of MTD were always lower than the true MTD. For
simplicity, the percentage bias was expressed with positive
values in the simulation results. The percentage bias for all
derived initial doses was between 15% and 40% for all dose
escalation sequences (Fig. 3B). If the initial dose was between
the 10th and 60th percentile of the derived initial dose range
then the percentage bias was similar for all dose escalation
sequences (Fig. 3B). If the initial dose was below the 10th
percentile of the derived initial dose range, the percentage
bias was greater (Fig. 3B). GRIS yielded a smaller percentage
bias when the initial dose was above the median of the
derived initial dose range. In all four dose escalation se-
quences, the smallest percentage bias occurred when the
initial dose was above the 90th percentile of the derived initial
dose range.
Precision was defined as the number of successful simu-
lations (i.e., simulations that achieved the goal of establishing
anMTD) divided by the total number of runs in the simulation.
Higher precision represents a higher probability that the
initial dose chosen in that particular sequence would even-
tually establish an MTD. Precision was greater than 95% if the
initial dose was between the 10th and 50th percentile of the
derived initial dose range (Fig. 3C).
When taking all four metrics into considerations, results of
simulation with an FP constraint suggested that the initial
dose should be between the 10th and 50th percentile of the
derived initial dose range for all four dose escalation
sequences.
We performed simulations in whichwe considered various
values of b in the logit function and showed that the calcu-
lated initial dose range changed smoothly with b. The sug-
gested initial doses (10th to 50th percentile of the derived
Fig. 3 e Sample size, number of DLTs, and bias and precision of MTD estimate versus percentile of the initial dose range. (A)
Sample size and number of DLTs, (B) percentage bias, and (C) precision of the MTD estimate calculated using a logit DLT
function with a [ L5.3 and b [ 0.695 for each for the four dose escalation sequences. The individual deviation of DLT
probability was distributed as N(0, 1.44). The x axis is the percentile of the derived initial dose range that was used as the
initial dose. The left y axis in (A) represents the sample size used in the escalation process, and the right y axis in (A)
represents the number of DLTs that occurred in the escalation process. DLT [ dose-limiting toxicity; MTD [ maximum
tolerated dose.
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was calculated with different values of b. Most importantly,
the simulation demonstrated that the total sample size,
number of DLTs, and percentage bias were similar across
different values of bwhen themedian of the initial dose range
was selected as the initial dose. The metrics derived from the
simulation provide strong evidence for this (Fig. 4).
Fig. 5 demonstrates that the relation among variability (s)
and sample size, number of DLTs, and percentage bias was
similar for all four dose escalation sequences. The required
sample sizes were similar for all assumed values of s. How-
ever, the percentage bias of the estimatedMTD increasedwith
variability. These findings were the same for all four dose
escalation sequences.Fig. 4 e Sample size, number of DLTs, and accuracy of bdMTD with
different b values was used for all dose escalation sequences. Th
initial dose, and the individual deviation of the DLT probability w
the sample size used in the escalation process, and the right y ax
escalation process. DLT [ dose-limiting toxicity.3.2. Comparison with published data
The sample size and number of DLTs obtained with the pro-
posed simulation method were compared with two published
Phase I cancer trials: the use of holmium-166 radio-
embolization (166Ho-radioembolization) for patients with
unresectable, chemorefractory liver metastases [14] and the
use of vandetanib for patients with recurrent malignant gli-
omas [15]. Both studies had a 3 þ 3 design with an MCDIS dose
escalation sequence.
The 166Ho-radioembolization study used 20 Gy as the initial
dose and found 60 Gy to be theMTD. The total sample sizewas
15, and there were three DLTs [14]. Using the proposed
approach with FP ¼ 20% and MCDIS, the derived values of adifferent b values. A logit DLT function with a[L5.3 and
e median of the derived initial dose range was used as the
as distributed as N(0, 1.44). The left y axis in (A) represents
is in (A) represents the number of DLTs that occurred in the
Fig. 5 e Sample size, number of DLTs, and accuracy of bdMTD with different s values. A logit DLT function with a[L5.3 and
b [ 0.695 and different individual s values was used for all dose escalation sequences. The median of the derived initial
dose range was used as the initial dose. The left y axis in (A) represents the sample size used in the escalation process, and
the right y axis in (A) represents the number of DLTs that occurred in the escalation process. DLT [ dose-limiting toxicity.
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11.43e51.53 Gy. If themedian of this range (30 Gy) was used as
the initial dose, our method predicted an MTD of 60 Gy with a
required sample size of 9.7 and 2.8 DLTs.
The vandetanib study used 100 mg as the initial dose and
found 100mg to be theMTD. The total sample sizewas 10, and
there were three DLTs [15]. Using the proposed approach with
FP ¼ 20% and MCDIS, the derived values of a and bwere 5.29
and 0.024, and the initial dose range was 33.33e150.32 mg. If
the median of this range (90 mg) was used as the initial dose,
our method predicted an MTD of 180 mg with a required
sample size of 9.3 and 2.7 DLTs. Some other studies confirmed
that the dose can be tolerated as high as 300 mg [22,23].4. Discussion
This study proposed and used an FP constraint and performed
several simulations to determine MTD using four different
dose escalation sequences. The results suggested that the
proposed method could be helpful for determining MTD with
a smaller sample size and less bias.
This study used a logit function to model the relation be-
tween dose and toxicity. The scale parameter b in the logit
function was estimated using a dose derived from animal
studies. The value of b is critical to the study because it greatly
affects the shape of the logit function and thus affects DLT
probability at each dose level. b represents the degree of
instantaneous increment in DLT probability. Mathematically,
it is inversely related to the size of the initial dose range. The
dose ranges calculated with different values of b overlapped
(Fig. 2), and the dose range from one particular b estimate was
largely covered by other b estimates with the same dose
escalation sequence, suggesting that the initial dose estimatemay be appropriate evenwhen the estimate of b deviates from
its true value.
Notably, with FS, SMFS, and MCDIS, the bias decreased to
20% when the initial dose was between the 70th and 100th
percentile of the initial dose range (Fig. 3B). With each dose
escalation, the second dose is twice as large as the initial dose.
Each initial dose is MTD if the DLT probability of the initial
dose is lower than the target DLT probability and the DLT
probability of the second dose is higher than the target DLT
probability. In this situation, the bias decreases as initial dose
increases. Although the MTD will have smaller bias and
require a smaller sample size, the precision of the simulation
with such initial doses will become much lower, reducing the
chances of successfully determining MTD.
In our method, the dose increment in MCDIS was depen-
dent on the initial dose. Some studies have used a constant
dose increment but different magnitude of initial dose [24,25],
and other studies have increased the dose with irregular in-
crements [26,27]. In practice, the dose increments should be
determined according to the pharmacological characteristics
of the drug. However, the relative increase of subsequent dose
increments will not change or will decrease for all four dose
escalation sequences.
There are a few limitations to this study. First, the pro-
posed method heavily relies on toxicity information from
animal studies, that is, LD10. Toxicity information from animal
studies is limited and can sometimes be confidential as it is
acquired in the early stages of drug development. Thus, one
should be cautious when estimating a and b in the logit
function. Second, we only considered a logit DLT function.
Although this is the most widely used function, other func-
tions can be used such as a hyperbolic tangent function. Third,
all MTD estimates heavily depend on the escalation scheme.
The 3 þ 3 design is one of the most common schemes in use
and is a special case of the A þ B design [4], but our proposed
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 2 ( 2 0 1 4 ) 5 5 6e5 6 2562method can also be extended to other, more complicated
schemes.
Our proposal of adding an FP constraint into the suggestion
of the initial dose will help the design of Phase I cancer trials,
making themmore efficient andmore economical. In general,
our study suggests that the median of the derived initial dose
range should be chosen as the initial dose of a Phase I study
regardless of the dose escalation sequence used.Conflicts of interest
All contributing authors declare no conflicts of interest.
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